FIELD: pharmaceutics.
SUBSTANCE: series of inventions discloses pharmaceutical compositions for treating diseases or conditions caused by effect of expression or activity of PCSK9 containing an antibody which specifically binds to human proprotein of subtilisin/keksin convertase type 9 (PCSK9).
EFFECT: use of compositions according to the series of inventions provides effective reduction of LDL-C level increasing HDL cholesterol level in serum, reduction of one or more of: levels of total cholesterol, ApoB levels, cholesterol not related to HDL-C, ratio of Apo-B/ApoA-1.
19 cl, 6 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS | 2012 |
|
RU2603481C2 |
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING SPECIFIC GROUPS OF INDIVIDUALS | 2012 |
|
RU2721279C2 |
| HIGH-AFFINITY HUMAN ANTI-PCSK9 ANTIBODIES | 2009 |
|
RU2552169C2 |
| HIGH AFFINITY HUMAN PCSK9 ANTIBODIES | 2009 |
|
RU2697773C2 |
| METHODS OF TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) | 2015 |
|
RU2735521C2 |
| METHODS OF TREATING PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASES HAVING HYPERCHOLESTEROLEMIA | 2015 |
|
RU2723018C2 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR | 2018 |
|
RU2772712C2 |
| TREATING WITH ANTI-PCSK9 ANTIBODIES | 2012 |
|
RU2576034C2 |
| APPLICATION OF ROSUVASTATIN (ZD-4522) IN TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | 2001 |
|
RU2294744C2 |
| PCSK9 ANTAGONISTS | 2009 |
|
RU2528735C2 |
